Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy - The Phase II/III RAMIRIS STUDY
A national, prospective, non-interventional study (NIS) of nivolumab plus chemotherapy in first-line treatment of gastric, gastro-oesophageal junction or oesophageal adenocarcinoma and oesophageal squamous cell carcinoma (ESCC) and nivolumab plus ipilimumab in ESCC
